Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,710,886
  • Shares Outstanding, K 58,592
  • Annual Sales, $ 54,030 K
  • Annual Income, $ -412,780 K
  • EBIT $ -472 M
  • EBITDA $ -474 M
  • 60-Month Beta 0.89
  • Price/Sales 32.78
  • Price/Cash Flow N/A
  • Price/Book 1.48

Options Overview Details

View History
  • Implied Volatility 60.01% (-3.13%)
  • Historical Volatility 33.08%
  • IV Percentile 41%
  • IV Rank 9.92%
  • IV High 254.54% on 11/18/25
  • IV Low 38.58% on 05/21/25
  • Expected Move (DTE 17) 4.25 (14.92%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 519
  • Volume Avg (30-Day) 234
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 44,162
  • Open Int (30-Day) 52,651
  • Expected Range 24.23 to 32.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.82
  • Number of Estimates 6
  • High Estimate -1.76
  • Low Estimate -1.87
  • Prior Year -1.55
  • Growth Rate Est. (year over year) -17.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.04 +9.37%
on 02/09/26
31.02 -8.19%
on 02/24/26
+0.55 (+1.97%)
since 02/03/26
3-Month
24.16 +17.88%
on 12/22/25
31.02 -8.19%
on 02/24/26
+0.99 (+3.60%)
since 12/03/25
52-Week
22.24 +28.06%
on 11/19/25
46.00 -38.09%
on 11/18/25
-4.64 (-14.01%)
since 03/03/25

Most Recent Stories

More News
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO

NEW YORK , March 3, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agios Pharmaceuticals, Inc.:

AGIO : 28.48 (-2.47%)
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

PYRUKYND is the only medicine approved in the UAE for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia  NewBridge Pharmaceuticals, a regional specialty company,...

AGIO : 28.48 (-2.47%)
Agios Pharmaceuticals: Q4 Earnings Snapshot

Agios Pharmaceuticals: Q4 Earnings Snapshot

AGIO : 28.48 (-2.47%)
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

PYRUKYND ® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full year AQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approval...

AGIO : 28.48 (-2.47%)
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...

AGIO : 28.48 (-2.47%)
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

AQVESME™ (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approval Pre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter...

AGIO : 28.48 (-2.47%)
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...

AGIO : 28.48 (-2.47%)
U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemia...

AGIO : 28.48 (-2.47%)
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...

AGIO : 28.48 (-2.47%)
Stocks Settle Higher Before Nvidia Earnings

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up by +0.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +0.56%. December...

MSTR : 132.68 (-3.61%)
MPC : 211.98 (+1.03%)
GOOGL : 303.58 (-0.96%)
GTLB : 26.70 (+1.95%)
ADI : 338.99 (-3.81%)
COIN : 182.36 (-1.55%)
OXY : 53.68 (-0.98%)
DY : 403.49 (-3.64%)
^BTCUSD : 67,683.66 (-0.56%)
SPY : 680.33 (-0.88%)
QS : 6.54 (-5.08%)
MP : 61.40 (-3.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

See More

Key Turning Points

3rd Resistance Point 30.87
2nd Resistance Point 30.08
1st Resistance Point 29.28
Last Price 28.48
1st Support Level 27.70
2nd Support Level 26.91
3rd Support Level 26.11

See More

52-Week High 46.00
Fibonacci 61.8% 36.92
Fibonacci 50% 34.12
Fibonacci 38.2% 31.32
Last Price 28.48
52-Week Low 22.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar